Octreotid Bendalis (Octreotide)

Octreotide mimics the natural hormone somatostatin and binds to somatostatin receptors, primarily subtypes 2 and 5, on endocrine cells. This binding blocks adenylate cyclase activity, reduces intracellular calcium, and suppresses the secretion of multiple hormones, including growth hormone, insulin, glucagon, and serotonin.

The specific dose and administration schedule for Octreotid Bendalis are determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Healthcare professionals tailor the regimen to achieve optimal hormonal control while minimizing adverse effects.

Octreotid Bendalis should be used in pregnancy or while breastfeeding only if the potential benefit outweighs the possible risk to the fetus or infant. Clinicians evaluate each case individually, and patients are advised to discuss any concerns with their healthcare provider before starting therapy.

To request Octreotid Bendalis, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Octreotid Bendalis contains octreotide, which has a high affinity for somatostatin receptor subtypes 2 and 5, offering potent inhibition of hormone secretion. Compared with other analogs such as lanreotide, octreotide provides a well‑established efficacy profile for acute symptom control and is available in both short‑acting and long‑acting formulations.

Octreotid Bendalis should be stored refrigerated at 2 °C to 8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Proper cold‑chain handling ensures the stability and potency of the injectable solution.

Octreotid Bendalis is supplied as a sterile injectable solution for subcutaneous or intravenous injection. The route, injection site, and frequency are determined by the prescribing clinician, who will also provide instructions on preparation, dosing, and any necessary monitoring.

Serious risks include pancreatitis, severe hypoglycemia (especially in diabetic patients), cardiac arrhythmias, gallbladder complications such as cholecystitis, and rare anaphylactic reactions. Patients should be monitored closely for these events, and any sudden or severe symptoms should prompt immediate medical evaluation.

Octreotid Bendalis is contraindicated in patients with known hypersensitivity to octreotide or any of its excipients. Caution is also advised for individuals with severe hepatic impairment, uncontrolled diabetes, or active gallbladder disease, as these conditions may increase the risk of adverse effects.